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ENS                    Enteric nervous system  
FFA2                   Free fatty acid receptor 2 
FFA3                    Free fatty acid receptor 3 
GPR109A            G-protein coupled receptor 109A 
HRP                      Horseradish peroxidase 
5-HIAA                5-hydroxyindoleacetic acid 
5-HIAL                5-hydroxyindole-3-acetaldehyde 
5-HT                     5-hydroxytryptamine 
5-HTOL               5-hydroxytryptophol 
IBD                       Inflammatory bowel disease 
IBS                        Irritable bowel syndrome 
LDH                      Lactate dehydrogenase 
Olfr 78                  Olfactory receptor 78 
SCFA                    Short chain fatty acids  
TMB                     3,3’,5,5’-Tetramethylbenzidine (TMB) 
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The enteric nervous system (ENS) operates by an independent reflex activity and is often 
described as “the second brain”. By beginning in the oesophagus and extending down to the 
anus, it governs the function of the entire gastrointestinal tract (1,2). ENS regulates 
gastrointestinal motility, the peristaltic reflex, blood flow, absorption of nutrients and fluid 
secretion (2,3). A key neurotransmitter in the ENS is 5-hydroxytryptamine (5-HT), also known 
as serotonin. 5-HT transfers information from the gastrointestinal tract to the central nervous 
system and acts as a growth factor, promoting enteric neuronal development and survival (3). 
The gastrointestinal tract alone stands for approximately 90% of the total body production of 
5-HT, while the rest 10% is produced in the central nervous system and in the platelets (4).  
 
Gut microbiota and diet have recently been reported to affect the ENS and the 5-HT signalling 
in the gastrointestinal tract (3,5-7). Increasing evidence shows that the effect might be through 
the action of short chain fatty acids (SCFA) (3,6-9). SCFA are the main products in the bacterial 
fermentation of fibres (10,11) and form a link between the diet, the gut microbiota and the 
nervous system. This link is of interest, since gut microbiota has received increased attention 
for its complex influence on the human body and its involvement in several neurological and 
gastrointestinal diseases (12). Studies have reported changes in the composition of gut 
microbiota, the ENS and the 5-HT signalling in patients with irritable bowel syndrome (IBS) 
and inflammatory bowel disease (IBD) (13-16). Considering the increased incidence of these 
diseases in the past decade, understanding the link between the gut microbiota, diet and the 














1.1. The enteric nervous system (ENS) 
 
The ENS consists of sensory neurons, motor neurons and interneurons organized into two main 
types of plexuses, the submucosal plexus and the myenteric plexus (Figure 1). The myenteric 
plexus participates in the control of gastrointestinal motility and is situated between the 
longitudinal and the circular muscle layers (1,3). The submucosal plexus is located near the 
muscularis mucosae and can be divided into three separate neuronal sub plexuses: The inner 
Meissner´s plexus situated directly below the muscularis mucosae, the intermediate plexus 
situated close to the muscularis mucosae and the outer Henle´s plexus situated directly adjacent 
to the circular muscle layer of the gastrointestinal tract (2). The main part of the submucosal 
neurons participate in the control of electrolyte secretion, intestinal epithelia cell proliferation 
and the modulation of paracellular permeability via control of tight junction associated proteins 
(2).  As in all biological systems there are exceptions, and some of the submucosal neurons 














The ENS operates autonomously by an independent reflex activity and responds to mechanical 
and chemical stimuli in the gastrointestinal tract. Approximately two-thirds of the 
enteroendocrine cells, specialized hormone and peptide releasing cells found alongside the 
epithelial cells, synapse with neurons of the ENS (18).  
Figure 1. The anatomy of the enteric nervous system. SMP = Submucosal plexus.  
Figure from Furness J et al., 2012 (17).  
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Communication with the central nervous system is, however, important and occurs through the 
parasympathetic and sympathetic nervous system. Especially the vagus nerve plays an 
important role in the bidirectional communication between the central nervous system and the 
ENS (12). The vagus nerve is the tenth of the cranial nerves and the longest, extending from 
the brain to the heart, lungs, gastrointestinal tract and other organs in the abdomen. Vagal 
neurons also seem to synapse with enteroendocrine cells in the gastrointestinal tract, thus 
possibly forming a direct link between the brainstem and the gastrointestinal tract (18).  
 
 
The gut microbiota is defined as all bacteria found in the entire gastrointestinal tract. A 
healthy gastrointestinal tract contains up to 1000 different bacterial species in human and 
most of the bacteria resides in the colon (12). The gut microbiota is essential for maintaining 
intestinal homeostasis and health: It participates in the production of vitamin K, vitamin A, 
biotin, thiamine, folate and riboflavin, takes part in the digestion of fibres and affects the 
energy balance (12), the immune system (19,20) and the nervous system (3,20-25) (Figure 2).  
The gut microbiota affects the ENS via several mechanisms. It modulates the 5-HT signalling 
in the ENS and stimulates the differentiation as well as the maturation of neurons in the ENS 
(3). The gut microbiota is also reported to alter gene expression in neurons of the ENS (23) 
and to stimulate the activity of neurons (21,23).  Furthermore, the gut microbiota stimulates 
the vagus nerve (12,18) and inhibits sympathetic neurons originating from the central nervous 







Figure 2. The gut microbiota is important and affects the 
nervous system via the circulatory system and the vagus 
nerve. Figure from Spielman L et al., 2018 (12).  
1.2. The gut microbiota affects the ENS   
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1.3. SCFA – A link between diet, gut microbiota and the nervous system     
SCFA (short chain fatty acids) are defined as a group of molecules consisting of two to six 
carbon atoms. They are the major products of the bacterial fermentation of large carbohydrate 
complexes, but also smaller carbohydrate complexes and proteins (10,11). The main SCFA 
produced in the human colon are acetate, propionate and butyrate in the molar ratio 57:21:22 
(10) (Figure 3). The total luminal colonic concentration of SCFA is around 130 mM and the 
concentration of SCFA in blood is reported to be: portal 375±70 µM, hepatic 148±42 µM and 
peripheral 79±22 µM (10). It is, however, important to take into account that the concentration 
of SCFA in the human body varies significantly due to diet and the composition of gut 
microbiota. Furthermore, the circadian clock appears to affect the intestinal concentration of 







Figure 3. The main short chain fatty acids produced in human: Acetate, propionate and butyrate. They 
appear as anions in the body, due to the pKa value 5 (27). 
 
SCFA are absorbed from the intestinal lumen and enter the cell in several ways, by passive 
diffusion through the cell membrane, by active transport via monocarboxylic acid/ketone 
transporters (28) and by SCFA/HCO3-exchangers (27). SCFA are important energy sources for 
colonocytes in the gastrointestinal tract but are also able to act as signaling molecules 
(19,20,25,27) and regulators of gene expression (23,28). 
SCFA interact with four transmembrane G-protein coupled receptors: Free fatty acid receptor 
2 (FFA2), free fatty acid receptor 3 (FFA3) (19), G-protein coupled receptor 109A (GPR109A) 
(29) and olfactory receptor 78 (Olfr 78) (30). The receptors FFA2 and FFA3 are the most 
abundant receptors for SCFA in the gastrointestinal tract and the peripheral nervous system 




Acetate Propionate Butyrate 
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Table 1. The presence of receptor FFA3 and FFA2 in the gastrointestinal tract and the peripheral 
nervous system (20,25,27,31). FFA3 has furthermore been detected on endothelial cells in the 
vasculature and FFA2 on enteric leukocytes (20). Receptor GPR109A has been detected on epithelial 
cells in the ileum and colon (29), whereas receptor Olfr 78 has been detected in the renal juxtaglomerular 
apparatus and the olfactory epithelium (30). Detections were done in the mouse and rat.  
SG = Sympathetic ganglia. 
 
Region FFA3 FFA2 
Gastrointestinal tract   S cells          - 
 L cells L cells 
 Ghrelin cells          - 
 G cells         - 
 Cholecystokinin cells         -     
 Enterochromaffin cells Enterochromaffin cells 
 K cells K cells 




-                     
-   
Peripheral nervous system  Sensory neurons           - 
 
Motor neurons          - 
 
Enteric neurons          - 
 
Superior cervical ganglion          - 
 
SG of the thoracic trunk          
SG of the lumbar trunk 
         - 
         - 
 
Prevertebral ganglion          - 
 
Vagal ganglion          - 
 
Trigeminal ganglion           - 
 
Spinal dorsal root ganglion           - 








1.4. 5-HT in the gastrointestinal tract 
5-HT is an important neurotransmitter in the ENS, that was discovered by two independent 
research investigations (32,33). By activating intrinsic and extrinsic sensory neurons in the 
ENS, 5-HT participates in the regulation of normal functioning of the gastrointestinal tract, such 
as peristaltic contractions, intestinal motility and secretion of mucous (4,34). The action of 5-
HT is mediated by the 5-HT receptor family 5-HT1-5-HT7 (34). All receptors are 
transmembrane G-protein coupled metabotropic receptors, except the 5-HT3 receptor, that is a 
ligand-gated ion channel. The predominant 5-HT receptors in the gastrointestinal tract are 5-
HT3 and 5-HT4, located in the myenteric plexus, the submucosal plexus and on the vagus nerve 
(34).   
 
5-HT is synthesized from the essential amino acid tryptophan, that is converted by the rate-
limiting enzyme tryptophan hydroxylase to 5-HT (4) (Figure 4). The 5-HT synthesis takes place 
in the enterochromaffin cells, containing the rate-limiting isoform enzyme tryptophan 
hydroxylase 1 and in serotonergic neurons of the myenteric plexus containing the rate-limiting 
isoform enzyme tryptophan hydroxylase 2 (35,36). Most of the 5-HT synthesis takes place in 
the enterochromaffin cells. Enterochromaffin cells are a type of enteroendocrine cells found 
alongside the epithelial cells in the gastrointestinal tract (35). 5-HT is released from the 
enterochromaffin cells by exocytosis from storage granules. The release of 5-HT occurs 
predominantly from the basal membrane into small blood vessels and the lamina propria, where 
5-HT can interact with enteric neurones (4,8). Release of 5-HT occurs also from the apical 
membrane, into the lumen of the gastrointestinal tract (4). The release of 5-HT is triggered by 
mechanical, neurological and chemical stimuli (4,9).  
 
Figure 4. Tryptophan is converted by the rate-limiting enzyme tryptophan hydroxylase (A) to 5-
hydroxytryptophan. 5-hydroxytryptohan is further converted to 5-HT by the enzyme L-aromatic 
amino acid decarboxylase (B). Figure from Szeitz A et al., 2017 (4).   
A B 
    (serotonin)  
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5-HT is metabolized in the gastrointestinal tract, neurons, liver, kidneys and lungs to 5-hydroxy-
indole-acetic acid (5-HIAA) and 5-hydroxytryptophol (5-HTOL), which are excreted in the 
urine (4,37,38) (Figure 5). 5-HIAA is the main metabolite of 5-HT in humans, with urinary 
concentrations ranging from 5 to 40 μM. The urinary concentration of 5-HTOL is normally 















Figure 5. 5-HT is converted by monoamine oxidase A (A) to 5-hydroxyindole-3-acetaldehyde (5-
HIAL). 5-HIAL is then further converted to 5-HIAA by aldehyde dehydrogenase (B) or 5-HTOL by 






1.5. The gut microbiota affects the synthesis and release of 5-HT   
The gut microbiota affects 5-HT signaling in the ENS by inducing de novo synthesis of 5-HT 
and stimulating neuronal and mucosal 5-HT release (3,5-7). The absence of gut microbiota or 
depletion of gut microbiota with antibiotics decreases colonic tryptophan hydroxylase 1 
expression and circulating 5-HT levels (3,6). On the other hand, colonization of germ-free mice 
with human-derived gut microbiota stimulates colonic motility in vivo, increases the colonic 
tryptophan hydroxylase 1 levels and restores the concentration of 5-HT (3,6,7).  
 
1.5.1. Are SCFA able to stimulate the release of 5-HT and affect the ENS?      
Contradictory results exist regarding the effect of SCFA on the release of 5-HT from the 
gastrointestinal tract. SCFA have been reported to increase 5-HT levels in the duodenum and 
colon, increase the production of 5-HT in the enterochromaffin cells and to increase the 
expression of the rate limiting enzyme tryptophan hydroxylase 1 in the 5-HT producing 
enterochromaffin cells (6-9). SCFA facilitate gene expression by acting as histone deacetylase 
inhibitors (23,28). Histone deacetylase inhibitors inhibit deacetylation of histone proteins, 
thereby opening up the chromatin structure and facilitating gene expression. Furthermore, the 
receptors FFA2 and FFA3 have been detected on 5-HT producing enterochromaffin cells in the 
mouse duodenum and colon (27,31). Contrary to these findings, SCFA are also reported not to 
affect the release of 5-HT from isolated primary mouse enterochromaffin cells derived from the 
duodenum and colon (39).  
SCFA both stimulate and inhibit neuronal activity of the ENS. The stimulatory effect of SCFA 
is believed to occur via the release of 5-HT, since SCFA are reported not to increase motility in 
tryptophan hydroxylase 1 knock out mice (21). After distribution of SCFA, the release of 5-HT 
is reported to activate 5-HT3 receptors located on vagal sensory nerve terminals leading to 
colonic contractions (8) and 5-HT4 receptors located on sensory calcitonin gene-related 
peptide-containing nerve terminals triggering the peristaltic reflex in the colon (9). In contrast, 
SCFA have also been reported to inhibit neurons of the ENS by reducing the neuronally 
mediated contraction of the colon and decrease the peristaltic peak amplitude in the colon (40-
43). The inhibitory effects of SCFA are believed to occur via stimulated release of peptide YY, 
a gastrointestinal hormone inhibiting motility (42) and via activation of FFA3 in the myenteric 
plexus (44).  
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1.6. The aim of the study  
Most of the studies investigating the effect of SCFA on the release of 5-HT have been 
performed in the colon. To our knowledge studies investigating this matter along the entire 
gastrointestinal tract have not been done.  
The aim of the study was to answer two questions: Does butyrate stimulate luminal release of 
serotonin and if so, in which parts of the gastrointestinal tract does this possibly occur? These 
questions are of interest, due to the conflicting results regarding SCFA:s effect on 5-HT release 
and the importance of the 5-HT signalling in the ENS. Our choice to study the effect of butyrate 
is based on the literature, where butyrate has gained the most attention.  
We created a luminal perfusion system to investigate the effect of butyrate on 5-HT release 
from different parts of the gastrointestinal tract in an ex vivo setting. Luminal perfusion was 
previously used successfully in a study investigating the effect of SCFA in the proximal colon 
(8). 

















2. Materials and Methods   
 
2.1. Animals 
A total of 14 male Wistar rats (500-550g) were obtained from Janvier Labs (Saint-Berthevin, 
France). The animals were housed in individually ventilated cages in social groups of two rats 
in a specific-pathogen free animal facility with a 12-h dark/light cycle, an average room 
temperature of +22°C, and a relative humidity of 55%. Rat chow (2018 Teklad Global 18% 
Protein Rodent Diet, Harlan Laboratories, Madison, WI, USA) and tap water were available ad 
libitum.  
Before euthanasia, the animals were fasted for 4 h (6 am -10 am) with free access to water to 
minimize the amount of chymus in the stomach and intestines. The animals were euthanized by 
decapitation with a guillotine. The abdomen was opened and the stomach, duodenum (directly 
after the stomach), jejunum (10 cm from duodenum) and colon (3 cm from the caecum) were 
isolated. The isolated segments of duodenum, jejunum and colon were 4 cm long. To minimize 
tissue damage, both the animals and intestinal segments were kept on ice during tissue 
harvesting. The isolated intestinal segments were kept in small dishes containing Krebs buffer 
(116.0 mM NaCl, 4.6 mM KCl, 2.6 mM CaCl2·2 H2O, 1.2 mM MgSO4· 7 H2O, 24.9 mM 
NaHCO3, 1.2 mM KH2PO4 and 2.5 mM glucose, pH 7.5, +37°C, saturated with 95% O2 and 
5% CO2 gas). The isolated stomach and the intestinal segments of duodenum, jejunum and 
colon were cleaned from chymus by careful injections of Krebs buffer using a syringe.  The 
isolated stomach and the intestinal segments were weighted and stored on individual Petri 
dishes in cold Krebs buffer at +4°C before mounting them into the luminal perfusion system. 








2.2. Luminal perfusion of the stomach and the isolated segments of 
duodenum, jejunum and colon 
 
2.2.1. Setting up the luminal perfusion system  
The stomach and isolated segments of duodenum, jejunum and colon were used ex vivo in a 
luminal perfusion system created by Sofie Schubert and laboratory technician Päivi Leinikka. 
The perfusion system consisted of a thermostatically controlled water bath (Grant Instruments, 
Royston, England), four carbogen tubes (95%  O2 and 5% CO2 gas), two perfusion fluids (Krebs 
buffer only and sodium salt of butyric acid [Sigma-Aldrich, St. Louis, MO, USA] dissolved in 
Krebs buffer), perfusion tubes (ID 1.85 mm and ID 2.3 mm), a peristaltic pump (Ismatec, 
Barrington, IL, USA), thin thread (DG, Wayne, NJ, USA), a heating block and glass tubes 
(Figure 6). The thermostatically controlled water bath was used to prewarm the perfusion fluids 
to +37°C. The carbogen tubes were used to ensure a sufficient amount of oxygen in the 
perfusion fluids. The peristaltic pump was linked to four perfusion tubes, one for each sample. 
The perfusion flow rate was 1 ml/min. The smaller perfusion tubes (ID 1.85 mm) were used to 
transport perfusion fluid into the intestinal segments, while the wider perfusion tubes (ID 2.3 
mm) were used to transport the perfusion fluid out of the intestinal segments. Thin tread was 
used to fasten the intestinal segments to the perfusion tubes. The heating block was used to keep 
the intestinal segments at +37°C during the experiment. On the heating block was a dish for 
each sample, containing 0.9% NaCl solution. The 0.9% NaCl solution was used to maintain the 
osmotic pressure in the samples. The glass tubes were used to collect the luminal perfusion 
samples.  
Figure 6. The luminal perfusion system created by Schubert and Leinikka. O2 = 95% O2 and 5% CO2 
gas, B = butyrate 100 mM, K = Krebs buffer, PP = peristaltic pump, T = perfusion tubes, S = stomach,  




2.2.2. Testing the luminal perfusion system: Pilot experiments on butyrate 
concentration and time dependency 
The perfusion fluids used were oxygenated Krebs buffer (+37°C, pH 7.5) and oxygenated Krebs 
buffer containing three different concentrations (1 mM, 10 mM and 100 mM) of sodium 
butyrate (+37°C, pH 7.5). The perfusion flow rate was maintained at 1 ml/min.  
The isolated intestinal segments were mounted into the luminal perfusion system in the 
following order: Stomach, duodenum, colon and jejunum. Thin thread was used to fasten the 
intestinal segments to the perfusion tubes in the physiological direction. The flow rate was 
checked separately for each intestinal segment before beginning of the sample collection from 
the perfusion system. The samples from the perfusion system were collected during a time 
period of 60 min at 5 min intervals (Table 2). The collected perfusion samples were kept in ice 
and centrifuged with Multifuge 3L-R (Heraeus, Osterode, Germany) for 15 min at 20000 rpm 
at +4°C. The supernatant was collected, and pH was measured for each sample, as well as for 
the perfusion fluids, with the use of pH paper (pH-Fix 7.0-14, Fisherbrand). The supernatant 
was then stored in -80°C. The tissue samples were carefully taken from the luminal perfusion 
system, weighted and stored in -80°C. 
Table 2. The time points used in the pilot experiment. 
Time points & perfusion fluid Aim 
0-5 min, Krebs buffer Wash the tissue 
5-10 min, Krebs buffer Wash the tissue 
10-15 min, Krebs buffer Used as baseline  
15-20 min, 1 mM butyrate / Krebs buffer 
for controls 
Ensure that 1 mM butyrate reaches the 
intestinal segment in time for the next sample 
20-25 min, 1 mM butyrate / Krebs buffer 
for controls  
Study the effect of 1 mM butyrate 
25-30 min, 10 mM butyrate / Krebs 
buffer for controls  
Ensure that 10 mM butyrate reaches the 
intestinal segment in time for the next sample 
30-35 min, 10 mM butyrate / Krebs 
buffer for controls 
Study the effect of 10 mM butyrate 
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35-40 min, 100 mM butyrate / Krebs 
buffer for controls 
Ensure that 100 mM butyrate reaches the 
intestinal segment in time for the next sample 
40-45 min, 100 mM butyrate / Krebs 
buffer for controls  
Study the effect of 100 mM butyrate 
45-50 min, Krebs buffer  Used as an intermediate sample, butyrate still 
in the tissue 
50-55 min, Krebs buffer  Study changes in the release of 5-HT after 
perfusion with butyrate 
55-60 min, Krebs buffer Study changes in the release of 5-HT after 
perfusion with butyrate 
 
If clogging and swelling of the isolated stomach or the isolated segments of the duodenum, 
jejunum and colon occurred during the perfusion experiment, the angles of the perfusion tubes 
were corrected to more optimal and a syringe was used to remove the blockade.  
 
2.2.3. The acute and prolonged effects of butyrate on the 5-HT release    
The perfusion fluids used were the same as in the pilot experiments, Krebs buffer and a 100 
mM solution of butyrate. Also, the perfusion flow rate was the same as in the pilot experiments 
(1 ml/min).  
The experiments were done in the same way as the pilot experiment, with a few exceptions: 
The isolated stomach was first mounted into the perfusion system, while the isolated segments 
of duodenum, jejunum and colon were kept in cold oxygenated buffer in the refrigerator. The 
intestinal segments where then mounted one by one into the perfusion system. The collection 
of samples from the luminal perfusion system were done at 10 min intervals (Table 3). The 
samples were collected in glass tubes containing 0.1% ascorbic acid and the tubes were covered 






Table 3. The time points used for studying the acute effect of butyrate (I) and the prolonged effect of 
butyrate (II) on the 5-HT release.  
Time points & perfusion fluid  Aim I Aim II 
0-5min, Krebs buffer Wash the tissue Wash the tissue 
5-15 min, Krebs buffer Used as baseline Used as baseline 
15-20 min, butyrate / Krebs buffer 
for controls 
Ensure that butyrate 
reaches the tissue in time 
for the next sample 
    Ensure that butyrate 
reaches the tissue in time  
for the next sample 
20-30 min, butyrate / Krebs buffer 
for controls  
Study the acute effect of 
butyrate 
Study the effect of  
butyrate 
30-40 min, 
I. Krebs buffer  
II. butyrate / Krebs buffer for 
controls 
Used as an intermediate 
sample, butyrate still in  
the tissue  
 
Study the effect  
of butyrate 
40-50 min, 
 I. Krebs buffer  
II. butyrate / Krebs buffer for 
controls 
Used as a carry-over 
sample, butyrate not in the 
tissue  
 
Study the prolonged effect  
of butyrate 
50-60 min, 
I. Krebs buffer  
II. butyrate / Krebs buffer for 
controls  
Study changes in the 
release of 5-HT after 
perfusion with butyrate 
 




2.3. The oxidation rate of 5-HT  
Two identical collecting glass tubes containing 5-HT diluted in oxygenated Krebs buffer 
(+37°C, pH 7.5) were used for the experiment. One of the tubes were covered with aluminium 
foil, the other one was not covered with aluminium foil. A baseline sample was taken from each 
collecting tube before beginning of the experiment. Samples were then taken every 15 min. The 
total time of the experiment was 60 min to resemble the collection of samples from the luminal 
perfusion system. Likewise, the tubes were stored in ice during the entire experiment, as in the 




2.4. Homogenisation of the stomach and the isolated segments of duodenum, 
jejunum and colon  
A 0.5 cm piece was taken from the middle of the isolated stomach and the isolated segments of 
duodenum, jejunum and colon. The pieces where put in 500 µl ELISA buffer enriched with 
ascorbic acid (32 mM NaCl, 8 mM Na2HPO4, 2.7 mM KCl, 1.46 mM KH2PO4, 0.001% Tween, 
0.1% ascorbic acid, pH 6.3). Ascorbic acid was used to prevent 5-HT from oxidation. The 
samples were homogenized with Precellys 24 (Bertin Technologies, Montigny le Bretonneux, 
France) for 3 x 20 sec, 5500 rpm. To ensure that the cells were broken, the samples were 
sonicated for 10 sec, 20% with a VC 505 sonicator (Sonics and materials, Newtown, CT, USA). 
The sonicated samples were centrifuged for 15 min at 11000 rpm at +6°C with Centrifuge 
5415D (Eppendorf, Hamburg, Germany). The supernatant was collected and stored in -80°C 
for the 5-HT assay. The samples were kept in ice during the whole procedure.  
 
2.5. Measurement of 5-HT 
The 5-HT content of the collected samples from the luminal perfusion experiments and the 5-
HT content of the supernatant from the homogenisation experiment were assayed with a 5-HT 
high-sensitive ELISA kit (DLD, Hamburg, Germany). From the luminal perfusion experiments, 
five sample-collection time points were chosen: 5-15 min, 20-30 min, 30-40 min, 40-50 min 
and 50-60 min. The sample 5-15 min was used as a baseline. The collected samples from the 
luminal perfusion experiments were diluted with assay buffer 1:2 (duodenum, jejunum and 
colon) and 1:5 (stomach). The supernatant from the homogenisation experiment were diluted 
1:100 and 1:200 (stomach, duodenum, jejunum and colon). The 5-HT content in the samples 
underwent an acetylation reaction, were 5-HT was chemically derivatized to N-acetyl-5-HT. 
N-acetyl-5-HT competed for a fixed number of antiserum binding sites until the system was in 
equilibrium. Free antigen and antiserum complexes were removed by washing. Goat anti-
rabbit-IgG-peroxidase was used to detect the N-acetyl-5-HT antibody, bound to the solid phase 
N-acetyl-5-H. 3,3’,5,5’-Tetramethylbenzidine (TMB) was used as substrate, and the TMB /  
 
 




2.6. Measurement of 5-hydroxyindoleacetic acid (5-HIAA) 
The 5-HIAA content of the collected samples from the luminal perfusion experiment and the 
supernatant from the homogenisation experiment were assayed with a 5-HIAA ELISA kit 
(Nordic BioSite AB, Täby, Sweden). Only samples from the luminal perfusion experiment, 
where the prolonged effect of butyrate had been studied, were used. The same sample-collection 
time points as in the 5-HT assay, were used from the luminal perfusion experiment. 5-HIAA in 
the samples competed with a fixed amount of 5-HIAA on the solid phase for sites on the 
biotinylated detection antibody. Unbound sample and excess conjugate were washed away. 
Horseradish peroxidase (HRP)-Streptavidin was added, where after the reaction plate was 
incubated. TMB was used as substrate and was added after the incubation. The enzyme-
substrate reaction was terminated by the addition of a sulphuric acid solution. The colour 
change was monitored at 450 nm.  
  
2.7. Measurement of lactate dehydrogenase (LDH) 
The LDH content of the collected samples from the luminal perfusion pilot experiments was 
assayed by a LDH kit (Sigma-Aldrich, St. Louis, MO, USA). The collected samples from the 
luminal perfusion experiments were diluted with assay buffer 1:5 (stomach, duodenum, 
jejunum and colon). LDH reduced NAD to NADH, which was monitored at 450nm.   
 
2.8. Statistical analysis  
Normality of the data sets was tested with the Kolmogorov-Smirnov test. Based on these 
analyses the data sets from the luminal perfusion experiments were analysed using two-way 
ANOVA with Bonferroni post-hoc test and the data sets from the homogenisation experiment 
were analysed using independent samples t-test. The data are expressed as means. The degrees 
of freedom (Df) are reported in the two-way ANOVA analyses. Statistical calculations and 
figures of the results were made by GraphPad Prism 5 (GraphPad Software Incorporated, La 
Jolla, CA, USA). Data were considered statistically significant when p <0.05. 
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3. Results   
3.1. Pilot experiments on butyrate concentration and time dependency   
3.1.1. Setting up the luminal perfusion system  
The pilot experiments showed that the most optimal concentration of butyrate for the luminal 
perfusion experiment is 100 mM. The 100 mM butyrate solution had the strongest effect on the 
release of 5-HT compared to 1 mM and 10 mM solutions. The 5 min period for sample 
collection turned out to be too short and showed considerable variation in the concentration of 
5-HT. Thus, it was more profitable to collect samples in periods of 10 min.  
The isolated stomach took the longest time to mount into the perfusion system, due to the very 
thin oesophagus and the contracting pylorus. On the other hand, when mounted into the 
perfusion system, the isolated segments of duodenum and colon were more susceptible to tissue 
damage than the stomach and jejunum. Thus, we opted to mount the stomach first into the 
perfusion system, while keeping the other intestinal segments at + 4 ºC to minimize the risk for 
tissue damage.   
No changes in the pH value 7.5 of the collected perfusion samples nor of the perfusion fluids 
were observed during the experiment, even after administration of butyrate. This result indicates 
that it was not necessary to measure the pH value for each collected perfusion sample.   
 
 
3.1.2. 5-HT is susceptible to oxidation   
A distinct reduction in the level of 5-HT was seen after 45 min, without any added compounds 
(Figure 7). This is of importance to notice, because the collection of samples from the luminal 
perfusion system takes 60 min and the total length of the luminal perfusion experiment is 120 
min. The results showed that 5-HT is susceptible to oxidation and therefore, the sample 
collecting tubes should be covered with aluminium foil. To further minimize the risk of 5-HT 
oxidation, an antioxidant (ascorbic acid 0.1%) should be added to the collecting tubes already 















Figure 7. 5-HT is susceptible to oxidation and a reduction in the amount of 5-HT was observed after 45 
min. Covered tube = tube covered with aluminium foil, open tube = tube without aluminium foil.  
  
 
3.1.3. Viability of the isolated stomach and the isolated segments of duodenum, 
jejunum and colon    
The concentration of lactate dehydrogenase (LDH) in the collected luminal perfusion samples 
was measured to verify the viability of the isolated intestinal segments during the luminal 
perfusion experiment. LDH is an oxidoreductase enzyme, released when tissue damage occurs.  
The LDH concentrations did not show significant changes during the experiment, nor did they 
correlate with the released amount of 5-HT (data not shown). Thus, it was used only in the pilot 
experiments as an indicator of viability, but not in the experiments investigating the acute and 





3.2. The acute effect of butyrate   
Luminal perfusion of the isolated stomach and the isolated segments of duodenum, jejunum 
and colon with 100 mM butyrate for 10 min did not increase the release of 5-HT statistically 
compared to perfusion with Krebs buffer only (Figure 8).  
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Figure 8. Luminal perfusion with butyrate for 10 min in the stomach (A), duodenum (B), jejunum (C) 
and colon (D). A-D. Butyrate seems to have a positive trend-effect on the release of 5-HT in the stomach, 
where the release of 5-HT is the highest. A similar trend-effect cannot be seen in the duodenum, jejunum 











3.3 The prolonged effect of butyrate 
 
3.3.1 Butyrate has a positive prolonged trend-effect on the release of 5-HT in the 
gastrointestinal tract 
Luminal perfusion with butyrate for 45 min did neither increase the release of 5-HT in the 
isolated stomach nor in the isolated segments of duodenum, jejunum and colon (Figure 9).  
 
Stomach



























































































Figure 9. Luminal perfusion with butyrate for 45 min in the stomach (A), duodenum (B), jejunum (C) 
and colon (D). A-D. Butyrate did not significantly increase the release of 5-HT. A positive trend-effect 











3.3.2. 5-HT is released out of the tissue from the isolated gastrointestinal segments     
The homogenisation experiment was done to determine whether 5-HT is released into or out of 
the tissue of the isolated stomach and the isolated segments of duodenum, jejunum and colon. 
Butyrate did not increase the tissue concentration of 5-HT in the stomach, duodenum, jejunum 












































































Figure 10. The concentration of 5-HT in the homogenised stomach (A), duodenum (B), jejunum (C) 
and colon (D) after perfusion with butyrate for 45 min. A-D. Butyrate did not significantly increase the 








3.3.3. Butyrate stimulates significantly the release of 5-HIAA from the 
gastrointestinal tract  
5-HT is metabolised to stable 5-HIAA, thus the release of 5-HIAA was analysed from the 
luminal perfusate as an indicator of 5-HT release. Butyrate stimulated significantly the release 
of 5-HIAA from the isolated stomach and isolated segments of duodenum, jejunum and colon 
(Figure 11).  
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Figure 11. The release of 5-HIAA in the stomach (A), duodenum (B), jejunum (C) and colon (D) after 
perfusion with 100 mM butyrate for 45 min. A. The concentration of 5-HIAA was significantly 
increased by butyrate in the stomach (p=0.048). The concentration of 5-HIAA was the lowest in the 
stomach, compared to the duodenum, jejunum and colon. B-C. A significant increase in the 
concentration of 5-HIAA was observed in all isolated intestinal segments, duodenum: p=0.0024, 








4.1. General discussion   
The aim of the study was to answer two questions: Firstly, is butyrate able to stimulate the 
luminal release of 5-HT? Secondly, in which parts of the gastrointestinal tract does this possibly 
occur? These questions are of interest, due to the importance of the 5-HT signalling in the 
enteric nervous system. Our results show that butyrate significantly stimulates the release of 5-
HIAA, the main metabolite of 5-HT, in the stomach, duodenum, jejunum and colon. Butyrate 
seems also to have a positive trend-effect on the release of 5-HT itself in the stomach, 
duodenum, jejunum and colon, although, no significant findings were given.  
There are conflicting results regarding SCFA effect on the 5-HT release from the 
gastrointestinal tract. Fukumoto et al. (2003) reported a stimulatory effect in the rat proximal 
colon ex vivo, when administrating 50-200 mM SCFA for 9 min with luminal perfusion (8). 
They used a mixture of acetate, propionate and butyrate in the molar ratio of 65:20:15. Grider 
et al. (2007) reported likewise a stimulatory effect of SCFA on the release of 5-HT (9). They 
used a three-compartment flat-sheet preparation of the distal rat colon. Concentrations of 5 mM 
acetate, propionate and butyrate were separately administrated for 15 min to the preparation. 
Contradictory, Martin et al. (2017) reported no effect of SCFA on the release of 5-HT from 
isolated primary mouse enterochromaffin cells derived from the duodenum and colon (39). 
Martin et al. used a 2 h incubation and administered separately 1-100 mM acetate, 1-30 mM 
propionate and 1-30 mM butyrate to the isolated enterochromaffin cells. The difference in the 
reported results is likely due to the use of different methods, different tissue preparations and 
different concentrations of SCFA. 
Our results support the theory of SCFA stimulating the release of 5-HT (6-9). In line with 
Fukumoto et al. we created a luminal perfusion system and used ex vivo luminal perfusion as 
the main method (8). In contrast to Fukumoto et al. and Grinder et al. we perfused the isolated 
stomach and the isolated segments of duodenum, jejunum and colon for 10 min and 45 min 
with 100 mM butyrate. The longer perfusion time and perfusion with a high concentration of 
butyrate were motivated after conducting the pilot experiments. The 100 mM butyrate solution 
had the strongest effect on the release of 5-HT compared to 1 mM and 10 mM solutions in the 
pilot experiments.  
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In line with previous studies we showed that butyrate significantly stimulates the release of 5-
HIAA, the main metabolite of 5-HT, in the stomach, duodenum, jejunum and colon. Butyrate 
seems also to have a positive trend-effect on the release of 5-HT itself. We were not able to 
detect any effect of butyrate in the tissue concentration of 5-HT in the stomach, duodenum, 
jejunum or colon, indicating that 5-HT might be released into the intestinal lumen. The release 
of 5-HT is reported to occur predominantly from the basal membrane into small blood vessels 
and the lamina propria (4). Therefore, we were expecting a greater effect of butyrate in the 
tissue concentration of 5-HT. One reason why we were not able to detect any effect of butyrate 
might be due to the ex vivo preparation. No vasculature was present in the isolated intestinal 
segments, which might hinder 5-HT from reaching the deeper layers of the tissues.  
 
4.2. Limitations  
The luminal perfusion system we created possessed certain limitations that should be 
considered when interpreting our results. Parts of the mucosa could have been damaged in the 
stomach and the isolated segments of duodenum, jejunum and colon during the preparation and 
luminal perfusion. This is problematic, since the 5-HT producing enterochromaffin cells are 
located in the mucosa. We measured the concentration of LDH in the collected luminal 
perfusion samples to verify the viability of the isolated intestinal segments, but we did not make 
any microscopical evaluations after preparation and luminal perfusion.  
The stomach and isolated segments of duodenum, jejunum and colon were at risk of swelling 
due to the luminal perfusion. This might affect the results, since the release of 5-HT is triggered 
by mechanical stimuli (4,9). Likewise, the Krebs buffer used as perfusion fluid contained 
calcium and glucose, both of which have been reported to stimulate the release of 5-HT from 
enterochromaffin cells in vitro (35,39). The basal level of 5-HT might therefore be elevated. 
We suspect some level of cross-reaction between butyrate and the 5-HIAA ELISA kit, as the 
results of the 5-HIAA analysis showed exceptionally low variation. Despite our best efforts, we 
could not verify this matter at this time, but it should be investigated further in the future.  
In contrast to the results of the 5-HIAA analysis, there was a high variation in the 5-HT release 
between individual animals. The high variation might explain why we only saw a positive trend-
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effect in the release of 5-HT when investigating the acute and prolonged effects of butyrate but 
were not able to reach statistical significance.   
The circadian clock is reported to affect the concentration of SCFA and the expression of 
receptor FFA3 in the colonic myenteric plexus in mice (26). This interesting finding leads to 
the question whether the expression of FFA3/2 on the enterochromaffin cells is controlled by 
the circadian clock in rats. If so, that may affect our results since rats are nocturnal animals and 
our animals were euthanised at 10 am. The expression of the receptors for SCFA are presumably 
low in the morning, which would lead to less binding of SCFA to the receptors on the 
enterochromaffin cells and thereby to decreased release of 5-HT. If the hypothesis is confirmed, 
this might also explain why we saw only a positive trend-effect in the 5-HT results.   
 
 
4.3. Clinical aspects      
In IBD and IBS patients, changes in the composition of gut microbiota, the enteric nervous 
system and the 5-HT signalling have been reported (13-16). The most marked changes in the 
5-HT signalling are altered 5-HT synthesis (13,14) and reduced tissue level of 5-HT (16). Our 
findings indicate that butyrate increases the release of 5-HT in the gastrointestinal tract and is 
thereby possibly able to increase gut motility. Particularly, a stimulated release of 5-HT would 
be helpful in increasing the colonic transit in IBS patients suffering from constipation and 
patients with chronic constipation (14). However, an increased 5-HT level could also be 
detrimental. In experimental colitis, 5-HT is reported to increase the production of 
proinflammatory cytokines from macrophages in mice (15) and to decrease bone formation in 
mice (127).  One should, however, consider that results from animal experiments cannot 









5. Conclusion  
Understanding the link between the gut microbiota, diet and the enteric nervous system might 
be of significant importance in the prevention and treatment of gastrointestinal disorders. This 
study showed that butyrate increases the release of 5-HIAA, the main metabolite of 5-HT, from 
the stomach, duodenum, jejunum and colon. An important benefit of our study was to create a 
luminal perfusion system for the ex vivo investigations.  
Butyrate seems also to have a positive trend-effect on the release of 5-HT itself in the stomach, 
duodenum, jejunum and colon. If this trend-effect could be confirmed by e.g. in vivo animal 
experiments, we should apply these observations in humans with gastrointestinal distress. 
Although, there is a future potential for preventing gastrointestinal disorders with the help of 
diet and gut microbiota, the clinical importance of our results should be considered carefully.  
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